Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12873284 | 0.94 | LMNA (0.46) | KMT2AMEN1MDM2LMNACASP3 | |
| SCHEMBL12555211 | 0.92 | KMT2A (0.47) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL7772788 | 0.91 | KMT2A (0.46) | KMT2AMEN1MDM2HPGDCASP3 | |
| SCHEMBL13523948 | 0.91 | KMT2A (0.46) | KMT2AMEN1MDM2HPGDCASP3 | |
| SCHEMBL3367289 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2LMNAHPGD | |
| SCHEMBL14416300 | 0.89 | KMT2A (0.42) | KMT2AMEN1MDM2LMNAHPGD | |
| SCHEMBL20143503 | 0.89 | KMT2A (0.42) | KMT2AMEN1MDM2LMNACASP3 | |
| SCHEMBL1745934 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2LMNAHPGD | |
| SCHEMBL31146900 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2LMNAHPGD | |
| SCHEMBL29470540 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528104-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | EPOR, PROKR1, EDNRB | KMT2A 4517/4885MEN1 3831/4885MDM2 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.